Successful treatment of pyoderma gangrenosum with granulocyte and monocyte adsorption apheresis

Russo, Irene; Miotto, Serena; Colpo, Anna; Marson, Piero; Tison, Tiziana; Ferrazzi, Anna; Alaibac, Mauro

doi:10.1111/iwj.12684

Cited by 8 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AA remission can be induced without using steroids and sustained with GCAP and IFX. GCAP is reported to be useful for the treatment of IBD and PG (12,13). Indeed, Kato et al described a Japanese patient with AAs and Crohn's disease (CD) who showed improvement following treatment with GCAP (5).…”

Section: Discussionmentioning

confidence: 99%

Rapidly Progressing Aseptic Abscesses in a Patient with Ulcerative Colitis

Yamaguchi

Nakagawa

et al. 2021

Intern. Med.

View full text Add to dashboard Cite

Aseptic abscesses (AAs) are extraintestinal manifestations of inflammatory bowel disease (IBD). IBDassociated AAs are rare in Japan. We treated a 45-year-old man with ulcerative colitis (UC)-associated AAs. During remission, multiple progressive abscesses were detected in the spleen; he underwent splenectomy because an infectious disease was suspected. Although his condition improved temporarily after splenectomy, a large liver abscess was noted, and a diagnosis of UC-associated AAs was made. Granulocytapheresis (GCAP) and infliximab (IFX) administration resolved the abscess. This is the first reported case of UC-associated AAs in a Japanese patient treated by splenectomy, GCAP, and IFX.

show abstract

Section: Discussionmentioning

confidence: 99%

Rapidly Progressing Aseptic Abscesses in a Patient with Ulcerative Colitis

Yamaguchi

Nakagawa

et al. 2021

Intern. Med.

View full text Add to dashboard Cite

show abstract

“…Treatments to control inflammation include topical agents (corticosteroids [13], tacrolimus [14], and cyclosporine [15]), intralesional agents (corticosteroids [16] and cyclosporine [17]), and systemic agents (oral corticosteroids [18], oral cyclosporine [15], and infliximab [19]). Other biologic agents (etanercept [20] and adalimumab [21]), granulocyte apheresis [22], and thalidomide [23] have been reported to have successful outcomes.…”

Section: Discussionmentioning

confidence: 99%

Peritoneal Dialysis Exit Site Pyoderma Gangrenosum: A Case Report

Anwar

Holfeld

Prasad³

2018

Case Rep Nephrol Dial

View full text Add to dashboard Cite

Background: Pyoderma gangrenosum (PG) is a rare, chronic inflammatory condition exhibiting mucopurulent or hemorrhagic exudates. The majority of cases are associated with inflammatory bowel disease, rheumatological diseases, and hematological malignancies. In the absence of typical serological markers and specific histopathological changes, the diagnosis is often clinical. Being rare, it is frequently misdiagnosed, which leads to a delay in instituting appropriate therapy. Case Presentation: We present a 53-year-old male of Aboriginal descent with end-stage renal disease due to diabetes who underwent insertion of a peritoneal dialysis (PD) catheter. Five weeks after PD catheter insertion, he started to notice a painful ulcer surrounded by a bed of erythema. The lesion eventually progressed to a purulent, hemorrhagic ulcer surrounded by a raised, irregular, violaceous border along the entirety of the PD catheter tunnel. There was no history of underlying systemic diseases commonly associated with PG. The catheter was removed, and an elliptical biopsy was taken, which ruled out infection, malignancy, and vasculitis. The changes were felt to be consistent with PG. The patient underwent treatment initially with topical corticosteroids, followed by oral prednisone, which unfortunately worsened his diabetic control; due to this, he was transitioned to cyclosporine, with complete resolution. Conclusions: Lesions at the PD catheter exit site are usually treated for infections. However, for ulcers that are painful, rapidly expanding, nonhealing, and unresponsive to antibiotics, PG should be considered as a differential diagnosis. This is the first reported case of PG occurring at the exit site of a PD catheter.

show abstract

“…oral corticosteroids, CsA, tacrolimus, colchicine, dapsone, MTX, intravenous immunoglobulin) and targeted therapy, including TNF-α inhibitors, anti IL-1 and IL-12/23 antagonists (42). Alternatively to current existing therapies, GMA is an effective option with minimal side effects, especially for steroid and immunosuppressant-resistant PG (43). Forty-nine cases of GMA application for PG have been summarized in Table II (28,(43)(44)(45)(46)(47)(48)(49)(50)(51)(52)(53)(54)(55)(56)(57)(58)(59)(60)(61)(62).…”

Section: Application Of Gma In Neutrophilic Dermatosesmentioning

confidence: 99%

“…Alternatively to current existing therapies, GMA is an effective option with minimal side effects, especially for steroid and immunosuppressant-resistant PG (43). Forty-nine cases of GMA application for PG have been summarized in Table II (28,(43)(44)(45)(46)(47)(48)(49)(50)(51)(52)(53)(54)(55)(56)(57)(58)(59)(60)(61)(62). In the main case series, Higashi et al (44) reported a complete response in eight patients, a nearly complete response in three patients and a partial response in two patients.…”

Section: Application Of Gma In Neutrophilic Dermatosesmentioning

confidence: 99%

Use of granulocyte and monocyte adsorption apheresis in dermatology (Review)

2022

Self Cite

View full text Add to dashboard Cite

Adsorptive granulocyte and monocyte apheresis (GMA) is an extracorporeal treatment that selectively removes activated myeloid lineage leukocytes from peripheral blood. This technique consists of a column with cellulose acetate beads as absorptive leukocytapheresis carriers, and was initially used to treat ulcerative colitis. A literature search was conducted to extract recently published studies about the clinical efficacy of GMA in patients with different skin disorders, reporting information on demographics, clinical symptoms, treatment and clinical course. Dermatological diseases, in which GMA has been performed, include generalized pustular psoriasis, pyoderma gangrenosum, palmoplantar pustular psoriasis, Behcet's disease, Sweet's syndrome, adult-onset Still's disease, impetigo herpetiformis, reactive arthritis, acne and hidradenitis suppurativa syndrome, cutaneous allergic vasculitis and systemic lupus erythematosus. In most patients, GMA was started after the failure of conventional therapeutic options and it was helpful in the majority of cases. Based on the information summarized, GMA could be considered a valid non-pharmacological treatment option for patients with several dermatological conditions, which are difficult to treat with other pharmacological preparations.

show abstract

Successful treatment of pyoderma gangrenosum with granulocyte and monocyte adsorption apheresis

Cited by 8 publications

References 22 publications

Rapidly Progressing Aseptic Abscesses in a Patient with Ulcerative Colitis

Rapidly Progressing Aseptic Abscesses in a Patient with Ulcerative Colitis

Peritoneal Dialysis Exit Site Pyoderma Gangrenosum: A Case Report

Use of granulocyte and monocyte adsorption apheresis in dermatology (Review)

Contact Info

Product

Resources

About